- Home
- ETNB vs APLT Comparison
ETNB vs APLT Comparison
Compare ETNB & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- APLT
- Stock Information
- Founded
- ETNB 2018
- APLT 2016
- Country
- ETNB United States
- APLT United States
- Employees
- ETNB N/A
- APLT N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- ETNB Health Care
- APLT Health Care
- Exchange
- ETNB Nasdaq
- APLT Nasdaq
- Market Cap
- ETNB 867.4M
- APLT 971.6M
- IPO Year
- ETNB 2019
- APLT 2019
- Fundamental
- Price
- ETNB $7.93
- APLT $8.69
- Analyst Decision
- ETNB Buy
- APLT Strong Buy
- Analyst Count
- ETNB 7
- APLT 5
- Target Price
- ETNB $30.33
- APLT $12.50
- AVG Volume (30 Days)
- ETNB 901.8K
- APLT 1.8M
- Earning Date
- ETNB 11-07-2024
- APLT 11-07-2024
- Dividend Yield
- ETNB N/A
- APLT N/A
- EPS Growth
- ETNB N/A
- APLT N/A
- EPS
- ETNB N/A
- APLT N/A
- Revenue
- ETNB N/A
- APLT N/A
- Revenue This Year
- ETNB N/A
- APLT N/A
- Revenue Next Year
- ETNB $133.30
- APLT $3,169.03
- P/E Ratio
- ETNB N/A
- APLT N/A
- Revenue Growth
- ETNB N/A
- APLT N/A
- 52 Week Low
- ETNB $7.00
- APLT $1.79
- 52 Week High
- ETNB $16.63
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- ETNB 42.09
- APLT 46.34
- Support Level
- ETNB $9.00
- APLT $9.44
- Resistance Level
- ETNB $10.01
- APLT $10.62
- Average True Range (ATR)
- ETNB 0.80
- APLT 0.62
- MACD
- ETNB -0.10
- APLT -0.13
- Stochastic Oscillator
- ETNB 8.52
- APLT 14.95
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.